Premature ovarian insufficiency (POI), the internationally accepted medical term, refers to the loss of normal ovarian function before the age of 40 years. Approximately 1 % of women worldwide are affected by premature ovarian insufficiency (POI) (International Menopause Society White Paper on POI, 2020).
Premature ovarian insufficiency (POI) not only disrupts normal physiological rhythm but also poses a significant challenge to reproductive planning. The cardinal symptom of premature ovarian insufficiency (POI) is menstrual irregularity: previously regular cycles may abruptly lengthen with reduced menstrual flow, progressing in severe cases to secondary amenorrhoea. Biochemically, serum follicle-stimulating hormone (FSH) exceeds 25 IU/L, oestradiol levels fluctuate and decline, and hypoestrogenic symptoms such as hot flushes and night sweats may occur. The aetiology of premature ovarian insufficiency (POI) is multifactorial, encompassing genetic factors, autoimmune disorders, iatrogenic causes (chemotherapy, radiotherapy, pelvic surgery), and modifiable lifestyle factors including chronic sleep deprivation, smoking, and extreme weight loss. Diagnosis requires integrated assessment of age, menstrual pattern, and hormonal profile. Early detection remains the cornerstone of effective management of premature ovarian insufficiency (POI).
The impact of premature ovarian insufficiency (POI) on fertility is profound. Ovarian function decline leads to premature depletion of the primordial follicle pool and arrested follicular development. Spontaneous pregnancy rates are only 3–5 %, and even with assisted reproductive technology, clinical pregnancy rates remain low at approximately 7.7 % (Nature Reviews Disease Primers, 2022 – “Premature ovarian insufficiency”). Furthermore, women with premature ovarian insufficiency (POI) face elevated risks of miscarriage, preterm delivery, obstetric complications, and fetal chromosomal abnormalities.
Management of premature ovarian insufficiency (POI) demands evidence-based fertility preservation and long-term health strategies. Timely childbearing remains the most effective preventive measure. High-risk individuals should undergo early ovarian reserve assessment, with oocyte or embryo cryopreservation offered when indicated. Long-term management must include lifestyle optimisation: regular sleep, moderate exercise, and balanced nutrition to improve endocrine status and mitigate progression of premature ovarian insufficiency (POI).
Nutritional supplementation serves as an important adjunctive approach. Juvenex Reco18 is a patented active compound extracted from leguminous plants. It is naturally present in follicular fluid and can act directly on ovarian somatic cells to reduces follicular atresia, promotes granulosa cell proliferation, promote occyte nutrient absorption, balance reproductive hormones, and optimize the follicular microenvironment, thereby providing evidence-based nutritional support for women with premature ovarian insufficiency (POI). Additionally, physician-guided hormone replacement therapy, serial reproductive hormone monitoring, and bone mineral density assessment effectively safeguard long-term health in patients with premature ovarian insufficiency (POI).
Although premature ovarian insufficiency (POI) may present insidiously, it is not insurmountable. Through scientific awareness, early intervention, appropriate protective measures, and evidence-based nutritional supplementation, the impact of premature ovarian insufficiency (POI) can be substantially reduced. Every woman should prioritise ovarian health, allowing science to serve as a robust shield against premature ovarian insufficiency (POI) and safeguard both reproductive potential and quality of life.